Marina Keil

Marina Keil

Auto-generated profile, based on publicly available information

Marina Keil

Research Unit Oncology, Merck Healthcare KGaA, the healthcare business of Merck KGaA, Darmstadt, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
MFManja Friese-Hamim
Manja Friese-Hamim
MRMaria J. Ortiz Ruiz
Maria J. Ortiz Ruiz
OBOlga Bogatyrova
Olga Bogatyrova
MKMarina Keil
Marina Keil
FRFelix Rohdich
Felix Rohdich
FZFrank T. Zenke
Frank T. Zenke
N-terminal processing by methionine aminopeptidases (MetAP) is a crucial step in the maturation of proteins during protein biosynthesis. Small-molecule inhibitors of MetAP2 have antiangiogenic and antitumoral activity. Herein, we characterize the structurally novel MetAP2 inhibitor M8891. M8891 is a potent, selective, reversible small-molecule inhibitor blocking the growth of human endothelial cells and differentially inhibiting cancer cell growth. A CRISPR genome-wide screen identified the tumor suppressor p53 and MetAP1/MetAP2 as determinants of resistance and sensitivity to pharmacologic MetAP2 inhibition. A newly identified substrate of MetAP2, translation elongation factor 1-alpha-1 (EF1a-1), served as a pharmacodynamic biomarker to follow target inhibition in cell and mouse studies. Robust angiogenesis and tumor growth inhibition was observed with M8891 monotherapy. In combination with VEGF receptor inhibitors, tumor stasis and regression occurred in patient-derived xenograft renal cell carcinoma models, particularly those that were p53 wild-type, had Von Hippel-Landau gene (VHL) loss-of-function mutations, and a mid/high MetAP1/2 expression score.

1 February 2024
Verified
Other
Open access
MFManja Friese-Hamim
Manja Friese-Hamim
MRMaria J. Ortiz Ruiz
Maria J. Ortiz Ruiz
OBOlga Bogatyrova
Olga Bogatyrova
MKMarina Keil
Marina Keil
FRFelix Rohdich
Felix Rohdich
FZFrank T. Zenke
Frank T. Zenke
Body weight curves for RCC PDX model RXF-2717-bearing mice treated with vehicle, M8891 (100 mg/kg, daily, per os), cabozantinib (10 mg/kg, daily, per os), or the combination are shown

1 February 2024
Verified
Other
Open access
MFManja Friese-Hamim
Manja Friese-Hamim
MRMaria J. Ortiz Ruiz
Maria J. Ortiz Ruiz
OBOlga Bogatyrova
Olga Bogatyrova
MKMarina Keil
Marina Keil
FRFelix Rohdich
Felix Rohdich
FZFrank T. Zenke
Frank T. Zenke
Body weight curves of gastric cancer PDX model GXF-1172-bearing mice treated with vehicle or M8891 (150 mg/kg, twice daily, per os) as monotherapy

1 February 2024
Verified
Other
Open access
MFManja Friese-Hamim
Manja Friese-Hamim
MRMaria J. Ortiz Ruiz
Maria J. Ortiz Ruiz
OBOlga Bogatyrova
Olga Bogatyrova
MKMarina Keil
Marina Keil
FRFelix Rohdich
Felix Rohdich
FZFrank T. Zenke
Frank T. Zenke
Treatment of three cell lines (bEND3, HT1080, HCT116) with MetAP2 inhibitors 1E−07 M TNP-470 or 1E−06 M A-832234 for 48 hours followed by IEF mobility shift separation of extracted protein lysates (lanes 1, 5, 9: protein marker).

1 February 2024
Verified
Other
Open access
MFManja Friese-Hamim
Manja Friese-Hamim
MRMaria J. Ortiz Ruiz
Maria J. Ortiz Ruiz
OBOlga Bogatyrova
Olga Bogatyrova
MKMarina Keil
Marina Keil
FRFelix Rohdich
Felix Rohdich
FZFrank T. Zenke
Frank T. Zenke
EF1a-1 knockdown (96 hours) in A549 or HCT116 cancer cells, which were treated for 24 hours with DMSO or 1E−07 M of M8891 and analyzed for the presence of MetEF1a-1 by Simple Western using the generated rabbit monoclonal antibody MKV-3-165-11.

1 February 2024
Verified
Other
Open access
MFManja Friese-Hamim
Manja Friese-Hamim
MRMaria J. Ortiz Ruiz
Maria J. Ortiz Ruiz
OBOlga Bogatyrova
Olga Bogatyrova
MKMarina Keil
Marina Keil
FRFelix Rohdich
Felix Rohdich
FZFrank T. Zenke
Frank T. Zenke
Increasing concentrations of M8891 (3E−09M to 1E−04M) were tested in an MetAP1 enzyme assay